







































AP-1 = activator protein-1; COX = cyclooxygenase; DCIS = ductal carcinoma in situ; ER = estrogen receptor; FNA = fine needle aspirate; HRT =
hormone replacement therapy; IEN = intraepithelial neoplasia; NSABP = National Surgical Adjuvant Breast and Bowel Project; RAR = retinoic acid
receptor; SERM = selective estrogen receptor modulator.
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Introduction
The demonstration by the National Surgical Adjuvant
Breast and Bowel Project that tamoxifen reduces breast
cancer risk by approximately 50% for at least some
groups of high-risk women was a milestone in the chemo-
prevention of breast cancer [1]. However, other than
women with a prior diagnosis of atypical hyperplasia, in
situ or invasive cancer, it is not clear what groups of
women receive enough benefit to offset the potential side
effects. These side effects include increased risk of men-
strual abnormalities and bone loss in young pre-
menopausal women, and increased risk of hot flashes,
sexual dysfunction, cataracts, uterine cancer, and throm-
boembolic phenomena in perimenopausal and post-
menopausal women [1–3]. Concerns about the
risk:benefit ratio, particularly in women over 50, have led
to the recommendation that this group not receive tamox-
ifen unless their short-term risk approaches 1% per year
for women with a uterus and 0.5% per year for women
without a uterus [4]. In the USA, many women are not
given the option of simultaneous tamoxifen and hormone
replacement for fear of increasing thromboembolic risk
[1,5]. Furthermore, it is clear that the incidence of estro-
gen receptor (ER)-negative cancers is not reduced with
preventive tamoxifen therapy and that some ER-positive
precancerous lesions might be resistant to tamoxifen [1].
Drug development
Important priorities for breast cancer prevention are to
develop a variety of new prevention agents that have fewer
side effects or a different side effect profile from that of
tamoxifen, that are compatible with hormone replacement
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therapy (HRT), and that are effective in ER-negative as well
as in tamoxifen-resistant ER-positive precancerous tissue.
To develop new drugs in a short period and at reasonable
cost, more efficient clinical testing models are being
developed for phase I and II prevention trials. These
models use potentially reversible morphological and mol-
ecular biomarkers that will enhance short-term risk pre-
diction, that will improve the probability of response by
matching the biomarker profile in precancerous tissue to
agents in the appropriate drug class, and that will be
used to assess response in a preliminary fashion before a
cancer incidence trial [6].
Biomarkers
Several potentially reversible biomarkers have been asso-
ciated with increased cancer risk, including mammo-
graphic breast density, insulin growth factor-1 and its
binding protein, serum estrogen and testosterone levels,
and intraepithelial neoplasia (IEN) [7–13]. IEN is probably
the risk biomarker most closely related to the underlying
neoplastic process [11]. IEN can be functionally defined
as a condition with morphological, molecular and genetic
abnormalities as well as an increased risk for breast
cancer. Using this definition, breast IEN can be viewed as
beginning with simple hyperplasia and extending through
atypical hyperplasia and in situ carcinoma.
Molecular alterations noted in at least a subset of IEN that
clamor for targeted intervention include the following: (1)
aberrant methylation and histone deacetylation of the pro-
moter region of many tumor suppressor genes [14–16];
(2) increased growth factor and growth factor receptor
expression/activation, resulting in increased mitogen-acti-
vated kinase activity; (3) increased cyclooxygenase-2
(COX-2) expression, tissue polyamines, angiogenesis and
protease activity [17–21]; (4) overexpressed ER and
hypersensitive ER variants [22,23]; and (5) increased aro-
matase and sulfatase activities, which result in increased
breast estrogen levels [24,25].
Potential agents
Histone deacetylase inhibitors combined with demethylat-
ing agents are promising as a means of rehabilitating
silenced tumor suppressor genes in ER-negative or ER-
positive precancerous tissue [26,27]. Inhibitors of acti-
vated tyrosine kinase, COX-2, metalloproteases, and
polyamine synthesis should also have activity in ER-nega-
tive as well as ER-positive tamoxifen-resistant precancer-
ous tissue. These types of agents might be used in
premenopausal women or postmenopausal women taking
HRT without altering the menstrual cycle or inducing hot
flashes [17,28]. The same can be said of monoterpenes
[29] and sulindac sulfone [30], which may act primarily to
induce apoptosis [31]. Several compounds such as difluo-
romethylornithine (an inhibitor of polyamine synthesis) and
perillyl alcohol (a monoterpene) are already in phase I–II
prevention testing, and trials for others such as celecoxib,
a COX-2 inhibitor, and ZD1839, a tyrosine kinase
inhibitor, are in the active planning stage [32–35].
New selective estrogen receptor modulators (SERMs)
that retain breast antagonist and bone agonist activity but
lack uterine agonist activity might have a more attractive
side effect profile than older SERMs such as tamoxifen
[36]. Two new agents, EM 652 and LY 353381
(Arzoxifene), are particularly attractive in that they might be
at least as efficacious as tamoxifen [37,38]. At present, it
is unknown whether either compound will be effective in
ER+ tissue which exhibits tamoxifen resistance due to ER
activation and gene transcription at AP-1 sites or ligand-
independent ER activation as a result of increased MAP
kinase activity. [36]. Alternatively, short course treatment
with pure anti-estrogens or SERMs plus tyrosine kinase
inhibitors may circumvent those tamoxifen types of resis-
tance [36,39,40].
Aromatase inhibitors/inactivators act by lowering periph-
eral and breast tissue estrogen levels. They do not
promote uterine cancer, and are associated with fewer
thromboembolic phenomena than tamoxifen [41]. Draw-
backs include hot flashes, lack of bone agonist effects and
unknown efficacy under conditions of moderate to high
circulating endogenous or exogenous estrogen levels
(premenopausal women or postmenopausal women
receiving HRT). However, in view of recent reports of their
equal or superior efficacy in direct comparison with tamox-
ifen in first-line metastatic and neoadjuvant studies
[41–43], prevention studies with anastrazole, letrazole and
exemestane are in the active planning stage in combina-
tion with bone-preserving agents such as oral biphospho-
nates or calcitonin nasal spray [44].
Hormonally targeted strategies not likely to result in men-
strual irregularities or hot flashes and thus likely to be
more attractive to young, premenopausal women include
the following: (1) soy/isoflavones, which might result in
less potent levels of estrogen or estrogen metabolites
[45]; (2) gonadotrophin-releasing hormone agonist regi-
mens combined with low-dose hormone replacement [46];
and (3) short-course hormonal combinations that mimic
pregnancy for nulliparous women in their late teens and
early twenties [47].
Retinoids, rexinoids and vitamin D analogues are also
undergoing active investigation in premenopausal and
postmenopausal women. These compounds might be
more active in ER-positive than in ER-negative precancer-
ous tissue [48]. Retinoids and vitamin D derivatives have
complex mechanisms of action, which include the promo-
tion of apoptosis through the upregulation of retinoic acid







































insulin growth factor levels [49–52]. In an Italian study
[53], fenretinide administration resulted in a decreased
incidence of contralateral breast cancer in premenopausal
women with stage I breast cancer undergoing adjuvant
treatment, and a phase II trial comparing fenretinide with
placebo in postmenopausal women receiving HRT is
nearing completion [54].
As RARb2 expression may be decreased in IEN through
hypermethylation, retinoids have been proposed as attrac-
tive partners for demethylating agents [27,55,56].
Because retinoids have demonstrated efficacy in tamox-
ifen-resistant cell lines, retinoids, rexinoids and deltanoids
might be paired with SERMs in the future [57,58]. Other
attractive combinations of chemoprevention agents
include SERMs and tyrosine kinase inhibitors or aro-
matase inhibitors/inactivators and COX-2 inhibitors.
Dose selection
The first hurdle to overcome in the course of the clinical
evaluation of some agents is often the selection of the
proper dose for prevention trials, which might be quite dif-
ferent than for treatment trials. In general, the dose
selected for prevention trials is that associated with
minimal side effects but one that nevertheless consistently
modulates biomarkers consistent with its mechanism of
action [59]. A popular mechanism for dose finding is the
presurgical model in which a diagnostic core biopsy for
ductal carcinoma in situ (DCIS) or a small invasive tumor
serves as the tissue sample for baseline biomarkers. Sub-
jects are randomized to one of several doses of drug
administered in the 2 weeks between core biopsy and re-
excision [6]. Because an early decrease in proliferation in
neoadjuvant studies seems to correlate with clinical
response to SERMs and aromatase inhibitors, the dose
selected is generally that associated with a consistent
decrease in proliferation [38,42,60].
Response evaluation
Once a dose has been selected, how can we efficiently
evaluate agents in a timely manner and at a reasonable
cost? The current National Surgical Adjuvant Breast and
Bowel Project Study of Tamoxifen and Raloxifene (STAR)
trial with an endpoint of cancer incidence is estimated to
require the enrollment of 22,000 subjects, will take
5–7 years to complete and will cost at least $200 million.
Could we use potentially reversible morphological and
molecular risk biomarkers to complete prevention trials in
a more expedient and less costly manner? We have
demonstrated in a prospective study that hyperplasia with
atypia observed in random periareolar fine needle aspi-
rates (FNAs) from high-risk women is associated with a
short-term risk of detection of DCIS or invasive cancer of
3% per year [61]. An increase in breast cancer risk has
also been noted for hyperplastic cells obtained from
nipple aspirate cytology [62].
Response to a prevention agent might be evaluated in a
preliminary fashion by sampling tissue before and after the
drug intervention and evaluating the reversal of atypical
cytological changes or the prevention of progression to
hyperplasia with atypia in the treated group in comparison
with a randomized control group. At the same time as
breast tissue is sampled at baseline for evidence of IEN,
molecular markers might be assayed to best match a sub-
ject’s precancerous tissue to a particular agent (such as
SERMs or aromatase inhibitors  for ER-positive precancer-
ous lesions). These strategies allow efficacy to be deter-
mined in a preliminary fashion with a fraction of the
subjects, cost, and time of a cancer incidence trial. A
phase II clinical trial, in which high-risk women with FNA
hyperplasia with or without atypia were randomized to a
polyamine synthesis inhibitor, difluoromethylornithine, or
placebo for 6 months and then reaspirated, performed
extremely well with consistent provision of material for
analysis, excellent subject acceptance, and rapid accrual
[32]. A phase II FNA study evaluating the SERM
arzoxifene is ongoing.
Drugs that show promising morphological and molecular
modulation in phase II trials might be moved into phase III
cancer incidence trials, where they would be compared with
standard prevention therapies. If the modulation of surro-
gate response biomarkers such as IEN can be validated as
being correlated with a reduced cancer incidence in phase
III trials, then prevention trials of the future might use IEN
instead of cancer incidence as their main study endpoint.
The concept of treatment and prevention of advanced IEN
is a paradigm shift that would markedly speed prevention
drug development across several disease sites; it is cur-
rently under active scrutiny by a special American Associa-
tion of Cancer Research Task Force.
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